The Melanoma Research Program at the NYU Cancer Institute is composed of investigators representing ten departments within the institute. The goal of the Melanoma Research Program is to reduce the morbidity and mortality of melanoma through focused translational research. The central scientific strategy of the program is to develop more precise diagnostic tools for individuals who are at risk of developing melanoma, and treatment strategies for those who have developed melanoma.
Under this unifying direction, the program has three major scientific objectives:
- Develop new predictive and prognostic models for patients with primary melanoma that integrate molecular biomarkers with clinical variables
- Discover the biologic heterogeneity of melanoma, with emphasis on molecular alterations that are associated with disease progression and drug resistance
- Develop and integrate emerging novel immunotherapeutic approaches with chemotherapeutic and biological therapies in the treatment of melanoma.
The Melanoma Research Program Members  have ongoing research projects  related to basic biology, diagnosis, management, and treatment. Because the program spans several disciplines it is able to address melanoma from many standpoints. At the NYUCI, the melanoma team includes leading physicians and scientists from Dermatology, Surgical Oncology, Neurosurgery, Medical Oncology, Pathology, Pharmacology, Environmental Medicine, Cell Biology, Chemistry, Biostatistics, Immunology, and Genetics.
The NYUCI is a National Cancer Institute-designated Center of Excellence.